Skin wound healing is a natural and intricate process taking place after injury, involving different sequential phases such as hemostasis, inflammatory, proliferative and remodeling that are associated with complex biochemical events. The interruption or failure of wound healing leads to chronic non-healing wounds or fibrosis-associated diseases constituting a major health problem where unfortunately medicines are not very effective. The objective of this study was to evaluate the capacity of Cicaderma® ointment to accelerate ulcer closure without fibrosis and to investigate wound healing dynamic processes. We used a necrotic ulcer model in mice induced by intradermal adriamycin injection and after eleven days, when the ulcer area is maximal, we applied vaseline or Cicaderma® every 2 days.
INTRODUCTION
Skin wound healing involves a series of complex processes that need the interaction of cytokines and growth factors produced by many different specialized cells. During normal wound healing, these orderly events can be classified in four overlapping phases including inflammation, formation of granulation tissue, re-epithelialization and matrix formation/remodeling. When these stages are delayed of more than a few weeks, wound consequently heals unusually slowly such as in diabetic foot ulcer (Jeffcoate and Harding, 2003) or more generally necrotic ulcer (Disa et al., 1998) . This defines clinically the chronic wound, one of the most common disorders, which severely impairs the quality of life of the patient and creates a huge financial burden on the healthcare system. Classically caused by a variety of events such as trauma, exposure to heat, cold, corrosive material or radiations, problems with blood circulation, skin ulcers are open wounds often accompanied by the sloughing of inflamed tissue. In order to improve this situation, many different therapeutic approaches have been tested to accelerate healing processes without fibrosis in the scar. For example, in several animal models for wound repair, a significant increase of healing was obtained by topic application of growth factors such as keratinocyte growth factor (Shannon et al., 2006; Henemyre-Harris et al., 2008) , basic fibroblast growth factor (Akita et al., 2008) , transforming growth factor (Cho et al., 2010) and platelet-derived growth factor (Yan et al., 2011) . However, costs and side effects restricted the use of these compounds and opened the way for new approaches like the use of protectors or co-receptors of these growth factors such as mimetics of endogenous sulfated glycosaminoglycans (Garcia-Filipe et al., 2007; BarbierChassefiere et al., 2009 ).
Since antiquity, plant extracts such as St. John's Wort (Hypericum perforatum L.), have been used to treat wounds within folk medicine in various countries. However, in the
MATERIALS AND METHODS

Animal model of skin ulceration
Housing of animals and anesthesia were performed following the guidelines established by the Institutional Animal Welfare with the European guide for care and use of laboratory animals. Standardized skin ulceration was performed by intra-dermal adriamycin (Doxorubicin Teva ® 0.2 %) injection on the shaved dorsum of male Swiss mice (Janvier, Le
Genest-St-Isle, France) as described previously (Barbier-Chassefiere et al., 2009) . Briefly, animals were anesthetized intraperitonally with sodium pentobarbital (Céva Santé Animale, Libourne, France). The back of the mice was shaved with a hair clipper and depilated with Veet ® depilatory cream. Two days after depilation, mice received 150 µL of a 2 mg/mL adriamycin solution by intra-dermal injection on the depilated area. The maximum of skin ulcer area was reached eleven days after adriamycin injection. This day (day 1) was the first day of treatment with Cicaderma® (Laboratoires Boiron, France) or vaseline (the main excipient of Cicaderma®) which were then applied topically every two days on the ulcer.
Ulcers were photographed every two days (i.e. 1, 3, 5, 8, 10, 12, 14, 17, 19 and 21) and cleaned until their complete closure. The lesion size was measured three times using the ImageJ software (Rasband, 1997 (Rasband, -2012 for each ulcer and the mean was calculated.
Biological samples for histological analysis were taken from sacrificed animals on days 1, 3, 5, 10, 17, 19 or 30 after the first application of the ointment whereas biochemical analysis were done on days 1, 5 and 10.
Histological studies
Skin samples were fixed in formaldehyde-buffered solution and embedded in paraffin wax. Serial 8 µm sections were prepared. Staining with Masson trichrome was used to study
Biochemical studies
Proteins were extracted from skin sample following manufacturer instructions with slight modifications. Skin biopsies were minced and incubated in the sample diluent buffer (from Quantibody® Mouse Inflammation Array 1, Raybiotech) for 1 h at 37 °C before homogenization using a Potter-Elvehjem glass-Teflon homogenizer. The homogenate was centrifuged for 5 minutes at 13 000g to remove debris and insoluble material. Aliquots of the supernatant were assayed for total protein content by BCA method or stored at -80 °C until analysis.
These protein extracts (200 µg/mL) were used with Quantibody® Mouse
Inflammation Array 1 (Raybiotech) to quantify forty cytokines in the kinetics of wound healing skin subjected to vaseline or Cicaderma® treatment. The binding of each cytokine on the membrane was revealed by autoradiography and quantified by the Protein Array Analyzer for ImageJ program developed for the ImageJ software (Carpentier, 2010) . Each assay was performed in duplicate from three mice per experimental group for each day tested.
Statistical analysis
All results reported in text and figures are the mean (±SEM) of independent determinations. Differences between the means in two groups were evaluated using Student's paired t test; p values < 0.05 were considered significant.
RESULTS
Ulcer area studies
Intradermal injection of adriamycin was previously reported to induce a necrotic skin ulcer, which regenerates spontaneously in mice and constitutes a good model to study the first phases of skin wound healing (Barbier-Chassefiere et al., 2009) . As shown in Fig. 1 Fig. 2) .
Histological studies a. Dermal reconstruction
The effects of Cicaderma® application on dermal reconstruction have been assessed by histological studies using Masson staining throughout ulcer closure,. On day 1, corresponding to the maximum of the ulcer area, the total destruction of the epidermis and dermis was clearly observed as compared with the mature healthy skin (Fig. 3a-b) . Then the different steps of the healing processes were followed daily. Major modifications including epidermal-cell proliferation, illustrated by thickening edges throughout the ulcer were noticed in both Cicaderma® and vaseline treated-mice. Interestingly, these effects occurred from day 2, just after one topical application of the ointment and were still persistent on day 5 (Fig. 3c-f ). On day 10, the reconstitution of organized skin layers seemed to proceed for the animals 1 0 treated with Cicaderma® and the thick skin still reflected an important activation (Fig. 3h) . In contrast, vaseline induced the production of new tissue in the dermis and hypodermis, but its organization seemed more anarchic (Fig. 3g) suggesting the development of fibrosis in these animals. These differences between the two treatments were still observed on day 17, mainly in layers below the epidermis that seemed better organized in Cicaderma® treated animals ( Fig. 3i-j) . This was confirmed by the organization of collagen (stained in green) which was less pronounced in sections treated with vaseline than in those treated with Cicaderma®.
Finally, at day 29 this results in a greater thickness of the epidermis in vaseline-treated animals than in Cicaderma®'s ( Fig. 3k-l) . Regarding the number of epithelial-cell layers, a faster maturation of epidermal structures is induced by Cicaderma®. Moreover the compact and organized dermis in the healing zone exhibited more common features with normal skin than the one observed with vaseline treatment.
b. Collagen organization
The histological studies also allowed us to compare collagen organization in the dermis treated with vaseline or Cicaderma® by Sirius red staining, which was visualized by polarized light. The collagen network was studied in the edges of the ulcer at early stages of wound healing (day 1, 3 and 5) or at later stages, inside the healing ulcer area. When the ulcer reached its maximal area (Fig. 4a) , collagen fibers displayed heterogeneity, appearing fragmented and with longer and disorganized fibers with horizontal and vertical crossing alongside. This was probably due to the normal degradation of these fibers by proteases in the ulceration processes. On day 32, collagen was more abundant, without any organization between fibers in vaseline-treated ulcers (Fig. 4b) . In contrast, treatment with Cicaderma® induced the presence of better defined intertwining fibers and reflecting the initiation of structural organization of collagen bundles (Fig. 4c) . This was confirmed distinctly on day 5
and 10 ( Fig. 4d-f vs e-g). At this time, collagen fibers of Cicaderma®-treated ulcers were slim 1 1
and well-defined with clear interlacements that reflected organization of these fibers, whereas the crosswise organization of collagen bundles was not so apparent for vaseline treatment.
When ulcers were finally closed, the collagen organization started to appear in vaselinetreated animals, while in those treated by Cicaderma® an increased amount of fibers and a better organization in collagen network were observed ( Fig. 4h-j vs i-k) .
c. Polymorphonuclears infiltration
Inflammation was evaluated through the measurement of PMNs recruitment at the edges of the ulcer (Fig. 5a ). The number of PMNs was high when the ulcer reaches its maximal area (day 1) and decreased by two fold on day 3 following the first treatment with vaseline. In contrast, the topical application of Cicaderma® maintained the high number of PMNs in the wound. On day 5, PMNs increased in the vaseline-treated group at the level of day 1, and diminished by 30% on day 10. Cicaderma® treatment allowed the progressive inhibition of PMNs recruitment until day 10, at levels significantly lower than with vaseline treatment, suggesting a reduction of inflammatory processes in the latter steps of wound healing.
d. Angiogenesis
CD31 staining was performed to analyze microvessel formation during the angiogenesis phase of wound healing (Vecchi et al., 1994) . Blood vessel density was not modified by either treatment, but significantly decreased at day 10, compared to day 3 and 5 ( Fig. 5b) .
Biochemical studies
a. Inflammatory status at the maximal ulcer area
Before evaluating whether Cicaderma® modulates the inflammatory response during the wound healing process, we first measured the level of forty inflammatory
1 2 cytokines/molecules in skin ulcer samples when the ulcer reached its maximal area (day 1) and compared it to normal skin ( Surprisingly, others known molecules involved in wound-healing such as IL-1α, IL-1β or GM-CSF were not significantly modified by the two treatments (data not show). Interestingly, the amounts of some anti-inflammatory cytokines were also reduced by topical application of the ointment. Cicaderma® reduced IL-4 level by 23% and maintained a stable level of IL-10 four days after the first application while vaseline increased IL-10 by about 40 % (Fig. 7a ).
1 3
G-CSF and M-CSF, described as hematopoietic molecules, were significantly reduced by Cicaderma®, whereas their amount was not influenced by vaseline compared to day 1 (Fig.   7a) . Moreover, the level of the metalloproteinase inhibitors TIMP-1 and TIMP-2 involved in collagens and extracellular matrix degradation were reduced after Cicaderma® treatment by 68 and 33 % respectively. Finally, the detection of Fas-Ligand, involved in the regulation of apoptotic cell death, was also diminished by 50% in Cicaderma®-treated ulcer compared to vaseline group (Fig. 7a ).
On day 10, the healing processes continued and we noticed that there were no statistical differences between the two treatments for the majority of proteins (27/ decreased by 29 and 26%, while the anti-inflammatory cytokine IL-13 was maintained stable close to the level observed on day 1 in Cicaderma®-treated ulcer, preventing the increase induced by treatment with vaseline ( Fig. 7b) . Lastly, vaseline application increased TIMP-2 by 25% whereas Cicaderma® reduced significantly the level by 18% (Fig. 7b ).
Interestingly, five molecules involved in inflammation IL-12p70, IL-4, M-CSF, MIP-1α, and TNF-α were significantly diminished both on days 5 and 10 ( regulation of these five molecules was probably implicated in epidermal-cell proliferation, in better collagen organization and quicker re-epithelialization of the skin. As for day 5, TNF-α, the major cytokine involved in inflammation, was maintained stable by Cicaderma® treatment, while vaseline-treated ulcer induced a higher level than at day 1 (Fig. 8a) .
However, the level of TNF-α with Cicaderma® remained higher than in healthy skin.
Whereas the level of M-CSF and IL12p70 in vaseline-treated ulcer remained unchanged from day 1 and close to those observed in normal skin ( Fig 
The hemostasis/inflammation phases
Eleven days after adriamycin injection, the area of the ulcer is maximal. Cell damage, blood vessels injury, degradation of collagen network induced by many toxic effects of adriamycin, including the production of an important oxidative stress, lead to clot formation.
This clot is considered as an important reservoir of molecules such as cytokines, growth factors which are involved in the chemoattraction of various cells during the early steps of healing (Frank et al., 2000; Marin et al., 2001) . In our ulcer model, eleven days after adriamycin injection, the expression of cytokines/molecules was completely modified compared to healthy skin (Fig. 5) . Among the numerous molecules classically involved in the early steps of hemostasis/ inflammation phases of wound healing, Rantes, MCP-1, MIP-1α, MIP-1γ, Eotaxin, Fractalkine were significantly increased, which correlates with the recruitment of inflammatory cells in the wound bed, as demonstrated by PMNs counting (Fig   5a) . PMNs are described as a major source of pro-inflammatory cytokines IL-1α, IL-1β, IL-6, and TNF-α, which are over-expressed in our ulcer model, to stimulate newly attracted
1 6 monocytes to differentiate into M1 macrophages. These pro-inflammatory cytokines can also be released by endothelial cells and peripheral blood monocytes in response to thrombin stimulation (Mahdavian Delavary et al., 2011) . In addition to these inflammatory cytokines,
we noticed a significant four fold increase in M-CSF, a hematopoietic cytokine described as an important chemoattractant for PMNs.
Effects of Cicaderma on the granulation phase
Interestingly, from its first topical applications (days 3 and 5), Cicaderma® induced a significant acceleration of ulcer closure as shown by the macroscopic measurement of the ulcer area. The effect of Cicaderma® allowed not only the recovery of a mature epidermal structure, a more compact and organized dermis, but also a rapid improvement of the collagen bundles organization close to mature healthy skin. Differences observed in collagen fibers network can be notably related to Hypericum perforatum L., which has been described as an 
Effects of Cicaderma on the angiogenesis and remodeling phases
In our ulcer model, the angiogenesis phase appeared to begin before day 5 as shown by the labeling of endothelial cells (Fig 6b) . On day 3, 5 and 10, angiogenesis was not modified by Cicaderma® treatment, but further studies should be used to confirm this finding.
However, Cicaderma® modified the pattern of Fractalkine, IL-13, IL-17, Lymphotactine, Rantes and SDF-1 only at day 10, whereas only IL-4, IL-12, MCP-1, M-CSF, TIMP-2 and TNF-α were decreased both on day 5 and 10. While highlighting the importance of these cytokines in the regulation of skin wound healing, these findings suggest that 1) the remodeling phase of the wound healing process starts between days 5 and 10, and 2), Cicaderma® treatment acts possibly on both re-epithelialization and remodeling phases. induced by Cicaderma®, could be therefore correlated to the diminution of PMNs in the wound bed, and would be of particular interest for improving healing and for reducing the risk of keloid scar formation. In addition, the slim, defined and well organized collagen fibers in Cicaderma®-treated group, reinforce the improved quality of the final remodeling of the wound, with less inflammation and no keloid scar formation.
In conclusion, this study demonstrated that Cicaderma® ointment, a mix of well known natural extracts, modulates inflammation, promotes re-epithelialization and accelerates skin wound healing in a skin ulcer model in mice (Fig. 9 ). This ointment can be proposed to accelerate the healing of small wounds, and its potential use in major diseases such as burns and radiodermatitis should be considered. Moreover, our data suggest the possibility it specifically regulates the first steps of wound healing through the modulation of a few cytokines, whose regulation clearly makes a potential target for new pharmacological therapies in chronic wounds pathologies. Finally, our data strengthen the emerging concept of a sequential treatment to improve wound healing and involving different pharmacological tools. 
L a n c e t 3 6 1 : and D17 respectively); (c, e, g, i) Cicaderma®-treated ulcer after 2, 4, 9 and 16 days of treatment (D3, D5, D10 and D17 respectively). Bar= 100 µm Statistical analysis was performed using Student's paired t test (*p < 0.05, **p < 0.01, ***p < 0.001). Cytokines were extracted as described in Materials and Methods and their quantification was done using Quantibody® Mouse Inflammation Array 1 from Raybiotech. Results are expressed as % of cytokine level measured at the maximum of the ulcer area (day 1) and represent the mean ± SEM of three animals in duplicate. Statistical analysis was performed using Student's paired t test (*p < 0.05, **p < 0.01, ***p < 0.001). Statistical analysis was performed using Student's paired t test (*p < 0.05, **p < 0.01, ***p < 0.001 vaseline vs cicaderma; #p < 0.05, ##p < 0.01, ###p < 0.001 compared to normal skin). Figure 9 . Sequence of events associated with normal and Cicaderma®-treated wound healing.
